Related Experiment Video
Updated: May 26, 2026

Profiling of Permethylated Mucin O-glycans Using Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Published on: June 20, 2025
Overview of the mucopolysaccharidoses
1Division of Genetics and Metabolism, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. muenzer@med.unc.edu
Insights
Mucopolysaccharidoses (MPSs) are rare genetic disorders affecting multiple organs. Early recognition by rheumatologists is crucial for timely diagnosis and improved outcomes for patients with these progressive lysosomal storage diseases.
Area of Science:
- Genetics
- Biochemistry
- Rheumatology
Background:
- Mucopolysaccharidoses (MPSs) are rare, inherited lysosomal storage disorders.
- Characterized by progressive, multi-system abnormalities and reduced life expectancy.
- Clinical manifestations include skeletal, joint, airway, cardiac, hearing, and vision issues, with severe forms causing intellectual disability.
Purpose of the Study:
- To provide an overview of MPS clinical features.
- To review current treatment options for MPS.
- To assist rheumatologists in recognizing and diagnosing MPS.
Main Methods:
- Literature review of MPS clinical features.
- Summary of available treatment modalities.
- Focus on the role of rheumatologists in early detection.
Main Results:
- MPSs present with diverse and progressive clinical features.
- Treatment options include hematopoietic stem cell transplantation and enzyme replacement therapy.
- Skeletal and joint abnormalities are key indicators for rheumatologists.
Conclusions:
- Early diagnosis and treatment of MPS can significantly improve patient outcomes.
- Rheumatologists play a vital role in identifying MPS due to characteristic musculoskeletal involvement.
- Increased awareness among rheumatologists can facilitate prompt diagnosis and referral for MPS patients.
Abstract:
The mucopolysaccharidoses (MPSs) are a group of rare, inherited lysosomal storage disorders that are clinically characterized by abnormalities in multiple organ systems and reduced life expectancy. The MPSs are heterogeneous, progressive disorders. Patients typically appear normal at birth, but during early childhood they experience the onset of clinical disease, including skeletal, joint, airway and cardiac involvement, hearing and vision impairment, and mental retardation in the severe forms of MPS I, MPS II and MPS VII and all subtypes of MPS III. There are two treatment options for patients with MPS that are directed at the underlying pathophysiology: haematopoietic stem cell transplantation, which is useful for selected patients, and recombinant i.v. enzyme replacement therapy, which is available for MPS I, II and VI. Early diagnosis and treatment can improve patient outcomes and may reduce the disease burden on patients and caregivers. As skeletal and joint abnormalities are characteristic of many patients with MPS, rheumatologists are positioned to recognize the features of the disease and to facilitate early diagnosis and referral. In this overview, the clinical features of the MPS disorders and a brief review of treatment options will be presented in order to aid the rheumatologist in recognizing the features of these rare genetic disorders.
Related Concept Videos
Proteoglycans
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Lysosomal Hydrolases
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Biosynthesis of Polysaccharides
Glycocalyx and its Functions
Components of...

